Related Experiment Video
Updated: May 7, 2026
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Drug treatment of pulmonary hypertension in children
Erika E Vorhies1, David Dunbar Ivy
1Division of Pediatric Cardiology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, C.S. Mott Children's Hospital, Ann Arbor, MI, USA.
Insights
Pediatric pulmonary arterial hypertension (PAH) is a serious condition. Current targeted vasodilator therapies improve quality of life and survival in children with PAH.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Vascular Medicine
Background:
- Pulmonary arterial hypertension (PAH) is a rare, severe pediatric condition.
- It involves progressive pulmonary vascular changes, leading to right heart failure and death.
- Most pediatric cases are idiopathic or linked to congenital heart disease.
Purpose of the Study:
- To review current drug therapies for pediatric pulmonary arterial hypertension (PAH).
- To discuss the application of these therapies in managing children with PAH.
- To highlight challenges in pediatric PAH management.
Main Methods:
- Review of current targeted pulmonary vasodilator therapies.
- Analysis of evidence-based adult studies and expert clinical experience.
- Focus on endothelin receptor antagonists, prostacyclin analogs, and PDE5 inhibitors.
Main Results:
- Targeted therapies demonstrate hemodynamic and functional improvements in children.
- Current treatments improve quality of life and survival, though not curative.
- Management relies on adult data and expert opinion due to limited pediatric-specific evidence.
Conclusions:
- Despite challenges, current drug therapies offer significant benefits for pediatric PAH.
- Further research and pediatric-specific guidelines are needed for optimal management.
- Effective management involves a combination of targeted vasodilators and expert clinical judgment.
Abstract:
Pulmonary arterial hypertension (PAH) is a rare disease in infants and children that is associated with significant morbidity and mortality. The disease is characterized by progressive pulmonary vascular functional and structural changes resulting in increased pulmonary vascular resistance and eventual right heart failure and death. In the majority of pediatric patients, PAH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease. Although treatment of the underlying disease and reversal of advanced structural changes has not yet been achieved with current therapy, quality of life and survival have been improved significantly. Targeted pulmonary vasodilator therapies, including endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase type 5 inhibitors, have demonstrated hemodynamic and functional improvement in children. The management of pediatric PAH remains challenging, as treatment decisions continue to depend largely on results from evidence-based adult studies and the clinical experience of pediatric experts. This article reviews the current drug therapies and their use in the management of PAH in children.
More Related Videos
10:03Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...